María Luisa Gutiérrez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Luisa Gutiérrez has a total of 295 co-authors. Here are the top co-authors by number of shared publications:
- Conrado Manuel Fernández Rodriguez
Service of Gastroenterology University Hospital Fundación Alcorcón Alcorcón Madrid Spain
21 shared publications - Manuel Romero-Gómez
UCM Digestive Diseases, Virgen del Rocio University Hospital, SeLiver Group, Institute of Biomedicine of Seville, Ciberehd, Department of Medicine, University of Seville, Seville, Spain
4 shared publications Emilio Suárez
Department of Hepatology, Hospital Nuestra Señora de Valme, Seville, Spain
3 shared publicationsJavier García-Samaniego
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain
3 shared publications- José Luis Calleja
Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, 28222 Madrid, Spain
3 shared publications M. Prieto
3 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8)
Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study
Background: Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR. Methods: We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment. Results: During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001). Conclusion: After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.
- 24 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8)
Open AccessCumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study
Background: Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR. Methods: We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment. Results: During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001). Conclusion: After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.
- 21 May 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (1) , 91-92
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
LINKED CONTENT: This article is linked to Gomez et al papers. To view these articles, visithttps://doi.org/10.1111/apt.18004andhttps://doi.org/10.1111/apt.18032
- 21 May 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (1) , 91-92
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
LINKED CONTENT: This article is linked to Gomez et al papers. To view these articles, visithttps://doi.org/10.1111/apt.18004andhttps://doi.org/10.1111/apt.18032
- 11 November 2022
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 46 (8) , 577-584
Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study
- 11 November 2022
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 46 (8) , 577-584
Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study
- 1 March 2021
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 44 (3) , 214-220
Plan asistencial coordinado para la eliminación del virus de la hepatitis C en el centro de ayuda integral al drogodependiente (CAID)
- 1 March 2021
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 44 (3) , 214-220
Plan asistencial coordinado para la eliminación del virus de la hepatitis C en el centro de ayuda integral al drogodependiente (CAID)
- 1 January 2018
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (2) , 129-133
Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents
Introduction: cases of hepatitis B virus (HBV) reactivation have been reported in patients with hepatitis C virus (HCV) treated with direct antiviral agents (DAA). Objectives and methods: the main objectives of the present study are: a) to determine the prevalence of HBV/HCV coinfection in HCV patients treated with DAAs in the Autonomous Community of Madrid (CM) and also to determine the incidence and clinical relevance of HBV reactivation; and b) to determine the HBV screening rates in HCV patients in our region. For that purpose, 1,337 HCV patients were consecutively treated with DAAs in two hospitals located in South CM between January 2015 and June 2017. Results: nine of the 1,337 (0.67%) participants were HBsAg positive and 356 (26.6%) had previous HBV infection markers. Two of the four (50%) HBsAg positive patients with untreated HBV developed a virological reactivation, but not a biochemical reaction. Of the 356 patients with previous HBV infection markers, all had normal transaminases at the end of treatment and during follow-up. The HBV screening rate amounted to 92.9% of the cohort. Conclusions: the prevalence of HBV (HBsAg positive) infection in patients with chronic hepatitis C in the southern area of the CM is low. HBV reactivation in HBsAg positive patients treated with DAAs is common, although without clinical relevance. In our region, there is a high rate of HBV screening in patients with HCV that are likely treated with DAAs.
- 1 January 2018
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (2) , 129-133
Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents
Introduction: cases of hepatitis B virus (HBV) reactivation have been reported in patients with hepatitis C virus (HCV) treated with direct antiviral agents (DAA). Objectives and methods: the main objectives of the present study are: a) to determine the prevalence of HBV/HCV coinfection in HCV patients treated with DAAs in the Autonomous Community of Madrid (CM) and also to determine the incidence and clinical relevance of HBV reactivation; and b) to determine the HBV screening rates in HCV patients in our region. For that purpose, 1,337 HCV patients were consecutively treated with DAAs in two hospitals located in South CM between January 2015 and June 2017. Results: nine of the 1,337 (0.67%) participants were HBsAg positive and 356 (26.6%) had previous HBV infection markers. Two of the four (50%) HBsAg positive patients with untreated HBV developed a virological reactivation, but not a biochemical reaction. Of the 356 patients with previous HBV infection markers, all had normal transaminases at the end of treatment and during follow-up. The HBV screening rate amounted to 92.9% of the cohort. Conclusions: the prevalence of HBV (HBsAg positive) infection in patients with chronic hepatitis C in the southern area of the CM is low. HBV reactivation in HBsAg positive patients treated with DAAs is common, although without clinical relevance. In our region, there is a high rate of HBV screening in patients with HCV that are likely treated with DAAs.
- Open Access
- 21 December 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 1-12
Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Hepatitis B virus (HBV) chronic infection affects up to 240 million people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC). HBV covalently closed circular DNA (cccDNA) plays an essential role in HBV persistence and replication. Current pharmacological treatment with nucleos(t)ide analogues (NA) may suppress HBV replication with little or no impact on cccDNA, hence lifelong treatment is required in the vast majority of patients. Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV. Recent promising developments targeting different molecular HBV life cycle steps are being pre-clinically tested or have moved forward in early clinical trials. We review the current state of the art of these pharmacological developments, mainly focusing on efficacy and safety results, which are expected to lay the ground for future HBV eradication. An inclusive literature search on new treatments of HBV using the following electronic databases: Pubmed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts and abstracts published over the last 12 years, from 2005 to March 2011 were reviewed for relevance and reference lists were crosschecked for additional applicable studies regarding new HBV antiviral treatment. HBV entry inhibitors, HBV core inhibitors, HBV cccDNA transcripts RNA interference, HBV cell apoptosis inducers, HBV RNA, viral proteins and DNA knock down agents, HBV release inhibitors, anti-sense nucleosides, exogenous interferon stimulation, interferon response stimulation and HBV therapeutic vaccines were reviewed. This review will provide readers with an updated vision of current and foreseeable therapeutic developments in chronic hepatitis B.
- 21 December 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 1-12
Open AccessUpcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Hepatitis B virus (HBV) chronic infection affects up to 240 million people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC). HBV covalently closed circular DNA (cccDNA) plays an essential role in HBV persistence and replication. Current pharmacological treatment with nucleos(t)ide analogues (NA) may suppress HBV replication with little or no impact on cccDNA, hence lifelong treatment is required in the vast majority of patients. Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV. Recent promising developments targeting different molecular HBV life cycle steps are being pre-clinically tested or have moved forward in early clinical trials. We review the current state of the art of these pharmacological developments, mainly focusing on efficacy and safety results, which are expected to lay the ground for future HBV eradication. An inclusive literature search on new treatments of HBV using the following electronic databases: Pubmed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts and abstracts published over the last 12 years, from 2005 to March 2011 were reviewed for relevance and reference lists were crosschecked for additional applicable studies regarding new HBV antiviral treatment. HBV entry inhibitors, HBV core inhibitors, HBV cccDNA transcripts RNA interference, HBV cell apoptosis inducers, HBV RNA, viral proteins and DNA knock down agents, HBV release inhibitors, anti-sense nucleosides, exogenous interferon stimulation, interferon response stimulation and HBV therapeutic vaccines were reviewed. This review will provide readers with an updated vision of current and foreseeable therapeutic developments in chronic hepatitis B.
- Open Access
- 12 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0184550
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain. Anti-HBc-positive, HBsAg-negative patients with undetectable HBV DNA were randomized to receive TDF 300 mg once daily (Group I) or observation (Group II). The primary endpoint was the percentage of patients showing HBV reactivation during 18 months following initiation of RTX treatment. Patients with detectable HBV DNA (Group III) received the same dose of TDF and were analyzed together with Group I to investigate TDF safety. Sixty-one patients were enrolled in the study, 33 in the TDF treatment group and 28 in the observation group. By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091). None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample. TDF was generally well tolerated and there were no severe treatment-related adverse events. In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
- 12 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0184550
Open AccessRandomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain. Anti-HBc-positive, HBsAg-negative patients with undetectable HBV DNA were randomized to receive TDF 300 mg once daily (Group I) or observation (Group II). The primary endpoint was the percentage of patients showing HBV reactivation during 18 months following initiation of RTX treatment. Patients with detectable HBV DNA (Group III) received the same dose of TDF and were analyzed together with Group I to investigate TDF safety. Sixty-one patients were enrolled in the study, 33 in the TDF treatment group and 28 in the observation group. By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091). None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample. TDF was generally well tolerated and there were no severe treatment-related adverse events. In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
- 11 January 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (3) , 784-793
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
Background Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. Aims To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. Methods Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP. Results A total of 611 patients were enrolled: 187 received entecavir and 424 tenofovir. Most were men, mean age 50 years, 32% cirrhotic and 16.5% HBeAg-positive. Mean follow-up was 55 (entecavir) and 49 (tenofovir) months. >90% achieved HBV DNA <69 IU/mL and biochemical normalization by months 12 and 36, respectively. Cumulative HBeAg loss and anti-HBe seroconversion were achieved by 33.7 and 23.8%. Four patients lost HBsAg; three HBeAg-positive. Renal function remained stable on long-term follow-up. Fourteen (2.29%) developed HCC during follow-up all of them with baseline Page-B ≥10. Nine were diagnosed within the first 5 years of therapy. This contrasts with the 27 estimated by Page-B, a difference that highlights the importance of regular HCC surveillance even in patients with virological suppression. Conclusions Entecavir and tenofovir achieved high biochemical and virological response. Renal function remained stable with both drugs. A Page-B cut-off ≥10 selected all patients at risk of HCC development.
- 11 January 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (3) , 784-793
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
Background Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. Aims To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. Methods Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP. Results A total of 611 patients were enrolled: 187 received entecavir and 424 tenofovir. Most were men, mean age 50 years, 32% cirrhotic and 16.5% HBeAg-positive. Mean follow-up was 55 (entecavir) and 49 (tenofovir) months. >90% achieved HBV DNA <69 IU/mL and biochemical normalization by months 12 and 36, respectively. Cumulative HBeAg loss and anti-HBe seroconversion were achieved by 33.7 and 23.8%. Four patients lost HBsAg; three HBeAg-positive. Renal function remained stable on long-term follow-up. Fourteen (2.29%) developed HCC during follow-up all of them with baseline Page-B ≥10. Nine were diagnosed within the first 5 years of therapy. This contrasts with the 27 estimated by Page-B, a difference that highlights the importance of regular HCC surveillance even in patients with virological suppression. Conclusions Entecavir and tenofovir achieved high biochemical and virological response. Renal function remained stable with both drugs. A Page-B cut-off ≥10 selected all patients at risk of HCC development.
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S718-S719
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S718-S719
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study
- Open Access
- 1 December 2016
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 3 (1) , e000104
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
Introduction Non-selective β-blockers (NSBBs) are widely prescribed in patients with cirrhosis for primary and secondary prophylaxis of bleeding oesophageal varices. Furthermore, it has been suggested that the clinical benefits of NSBBs may extend beyond their haemodynamic effects. Recently, a potentially harmful effect has been described in patients with refractory ascites or spontaneous bacterial peritonitis. Methodology A comprehensive literature search on β-blockers and cirrhosis survival using the electronic databases PubMed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts published over more than 35 years, from 1980 to April 2016 were reviewed for relevance and reference lists were cross-checked for additional pertinent studies regarding potential NSBB effects, especially focused on those concerned with survival and/or acute kidney injury (AKI). Discussion The proposed review will be able to provide valuable evidence to help decision making in the use of NSBB for the treatment of advanced cirrhosis and highlights some limitations in existing evidence to direct future research.
- 1 December 2016
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 3 (1) , e000104
Open AccessNon-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
Introduction Non-selective β-blockers (NSBBs) are widely prescribed in patients with cirrhosis for primary and secondary prophylaxis of bleeding oesophageal varices. Furthermore, it has been suggested that the clinical benefits of NSBBs may extend beyond their haemodynamic effects. Recently, a potentially harmful effect has been described in patients with refractory ascites or spontaneous bacterial peritonitis. Methodology A comprehensive literature search on β-blockers and cirrhosis survival using the electronic databases PubMed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts published over more than 35 years, from 1980 to April 2016 were reviewed for relevance and reference lists were cross-checked for additional pertinent studies regarding potential NSBB effects, especially focused on those concerned with survival and/or acute kidney injury (AKI). Discussion The proposed review will be able to provide valuable evidence to help decision making in the use of NSBB for the treatment of advanced cirrhosis and highlights some limitations in existing evidence to direct future research.